225-Ac-HER3-ARC

N/A

Report date: 2025/11/04 16:07:44

Base Information

Drug Name225-Ac-HER3-ARC

Drug Alias Name225Ac-HER3 ARC225-Ac-HER3-ARC225Ac-HER3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agent +[4]

Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesActinium Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesActinium Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A